OptiNose Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose or view top-rated stocks.

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OptiNose wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

OptiNose is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for OptiNose.

OptiNose, Inc. (NASDAQ:OPTN) released its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. OptiNose had a negative trailing twelve-month return on equity of 1,275.55% and a negative net margin of 179.55%.
View OptiNose's earnings history.

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPTN shares have decreased by 29.1% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19.

OptiNose updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $80 M-, compared to the consensus revenue estimate of $83.50 million.

3 brokers have issued 12-month target prices for OptiNose's stock. Their forecasts range from $10.00 to $19.00. On average, they expect OptiNose's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 280.7% from the stock's current price.
View analysts' price targets for OptiNose or view top-rated stocks among Wall Street analysts.

Some companies that are related to OptiNose include Sesen Bio (SESN), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Cara Therapeutics (CARA), Chimerix (CMRX), Ardelyx (ARDX), Rigel Pharmaceuticals (RIGL), Clene (CLNN), Calliditas Therapeutics AB (publ) (CALT), Esperion Therapeutics (ESPR), Bicycle Therapeutics (BCYC), Evolus (EOLS) and Spectrum Pharmaceuticals (SPPI).
View all of OPTN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose's stock is owned by many different institutional and retail investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (4.70%), BlackRock Inc. (4.62%), Massachusetts Financial Services Co. MA (3.35%), Opaleye Management Inc. (1.56%), Wasatch Advisors Inc. (1.45%) and Geode Capital Management LLC (1.05%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Morgan Stanley, Millennium Management LLC, Massachusetts Financial Services Co. MA, Goldman Sachs Group Inc., Nuveen Asset Management LLC, JPMorgan Chase & Co., and Cubist Systematic Strategies LLC. Company insiders that have sold OptiNose company stock in the last year include Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud, and Victor M Clavelli.
View insider buying and selling activity for OptiNose or view top insider-selling stocks.

OPTN stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Renaissance Technologies LLC, Snow Capital Management LP, GSA Capital Partners LLP, BlackRock Inc., Assenagon Asset Management S.A., Geode Capital Management LLC, and D. E. Shaw & Co. Inc.. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, Michael F Marino III, and Peter K Miller.
View insider buying and selling activity for OptiNose or or view top insider-buying stocks.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPTN stock can currently be purchased for approximately $3.59.

OptiNose has a market capitalization of $190.68 million and generates $49.12 million in revenue each year. The company earns $-99,790,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis.

OptiNose employs 204 workers across the globe.

The official website for OptiNose is www.optinose.com.

OptiNose is headquartered at 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]